[HTML][HTML] Lung cancer immunotherapy: progress, pitfalls, and promises
A Lahiri, A Maji, PD Potdar, N Singh, P Parikh, B Bisht… - Molecular cancer, 2023 - Springer
Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
[HTML][HTML] Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
VD de Jager, W Timens, A Bayle, J Botling… - The Lancet Regional …, 2024 - thelancet.com
For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies
have changed significantly due to the introduction of targeted therapies and immunotherapy …
have changed significantly due to the introduction of targeted therapies and immunotherapy …
Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
For advanced metastatic non-small-lung cancer, the landscape of actionable driver
alterations is rapidly growing, with nine targetable oncogenes and seven approvals within …
alterations is rapidly growing, with nine targetable oncogenes and seven approvals within …
[HTML][HTML] Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells
H Zhou, L Zhou, Q Guan, X Hou, C Wang, L Liu… - Communications …, 2023 - nature.com
Non-small cell lung cancer (NSCLC) is the most prevalent type of cancer and the leading
cause of cancer-related death. Chemotherapeutic resistance is a major obstacle in treating …
cause of cancer-related death. Chemotherapeutic resistance is a major obstacle in treating …
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions
J Zhong, H Bai, Z Wang, J Duan, W Zhuang… - Frontiers of …, 2023 - Springer
With the improved understanding of driver mutations in non-small cell lung cancer (NSCLC),
expanding the targeted therapeutic options improved the survival and safety. However …
expanding the targeted therapeutic options improved the survival and safety. However …
[HTML][HTML] HER2 alterations in non-small cell lung cancer: biologico-clinical consequences and interest in therapeutic strategies
E Loeffler, J Ancel, V Dalstein, G Deslée, M Polette… - Life, 2023 - mdpi.com
Lung cancer stands as the first cause of death by cancer in the world. Despite the
improvement in patients' outcomes in the past decades through the development of …
improvement in patients' outcomes in the past decades through the development of …
[HTML][HTML] Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
Introduction The magnitude of response to immune checkpoint inhibitor (ICI) therapy may be
sex-dependent, as females have lower response rates and decreased survival after ICI …
sex-dependent, as females have lower response rates and decreased survival after ICI …
[HTML][HTML] Quantifying the value of multigene testing in resected early stage lung adenocarcinoma
B Muthusamy, K Raskina, KT Lofgren, G Li… - Journal of Thoracic …, 2023 - Elsevier
Introduction Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs), each
requiring testing for precision biomarkers, have recently been approved in the adjuvant …
requiring testing for precision biomarkers, have recently been approved in the adjuvant …
[HTML][HTML] Treatment of advanced non-small cell lung cancer with RET fusions: reality and hopes
D Rocco, L Sapio, L Della Gravara, S Naviglio… - International Journal of …, 2023 - mdpi.com
RET-selective tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib have
revolutionized the landscape of RET-positive (RET+) advanced non-small cell lung cancer …
revolutionized the landscape of RET-positive (RET+) advanced non-small cell lung cancer …
[HTML][HTML] An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy
Simple Summary The recent evidence shows that patients with resectable non-small cell
lung cancer (NSCLC) benefit from the addition of immunotherapy to chemotherapy before …
lung cancer (NSCLC) benefit from the addition of immunotherapy to chemotherapy before …